Literature DB >> 14715829

Increased prevalence of regurgitant valvular heart disease in acromegaly.

Alberto M Pereira1, Sjoerd W van Thiel, Jonathan R Lindner, Ferdinand Roelfsema, Ernst E van der Wall, Hans Morreau, Jan W A Smit, Johannes A Romijn, Jeroen J Bax.   

Abstract

Cardiac involvement is common in acromegaly, but the prevalence of valvular abnormalities in patients with acromegaly has not been documented and is the topic of this study. In a prospective study design, 40 consecutive patients with acromegaly and 120 control subjects (matched for age, sex, hypertension, and left ventricular systolic function) were studied. All patients and controls were evaluated using conventional two-dimensional and Doppler echocardiography. Significant valve disease was more prevalent in acromegalics compared with controls (22% vs. 6.7%, respectively; P = 0.005). Aortic valve regurgitation (>/=>trace severity) was present in 30% of patients vs. 7% of controls (P < 0.001), and mitral regurgitation (>/=moderate severity) was absent in controls but present in 5% of acromegalics (P = 0.014 vs. controls). Binary logistic regression analysis showed a significant impact only for disease duration on valvular disease, with an odds ratio of 1.19 (95% confidence interval, 1.028-1.376; P = 0.019). Acromegaly is associated with an increased prevalence of regurgitant valvular heart disease. This is dependent on the duration of exposure to increased GH concentrations, with a 19% increase in odds per year. This increased prevalence of occult valvular disease indicates that these patients require appropriate follow-up care and monitoring, especially patients with inadequate control of GH overproduction.

Entities:  

Mesh:

Year:  2004        PMID: 14715829     DOI: 10.1210/jc.2003-030849

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend?

Authors:  A Colao; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 2.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

3.  Cabergoline treatment in acromegaly: cons.

Authors:  Leandro Kasuki; Leonardo Vieira Neto; Mônica R Gadelha
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

Review 4.  Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management.

Authors:  Ajay N Sharma; Marilyn Tan; Ezra A Amsterdam; Gagan D Singh
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

Review 5.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 6.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.

Authors:  Annamaria Colao
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

7.  Sudden death due to aortic rupture in acromegaly.

Authors:  Pietro Maffei; Carla Menegazzo; Mauro Michelotto; Roberto Salmaso; Chiara Martini; Eugenio De Carlo; Marta Carli; Martina Barban; Ambrogio Fassina; Roberto Vettor; Nicola Sicolo
Journal:  Heart Vessels       Date:  2008-02-14       Impact factor: 2.037

8.  Gross aortic root dilation in a young woman with acromegaly.

Authors:  Andrew Wiper; M Eisenberger; A McPartlin; M El-Omar
Journal:  Exp Clin Cardiol       Date:  2012

9.  The heart in sporadic inclusion body myositis: a study in 51 patients.

Authors:  Fieke M Cox; Victoria Delgado; Jan J Verschuuren; Bart E Ballieux; Jeroen J Bax; Axel R Wintzen; Umesh A Badrising
Journal:  J Neurol       Date:  2009-10-08       Impact factor: 4.849

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.